Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: A united states multicenter study

Head and Neck

Volumn 33, Issue 12, 2011, Pages 1683-1694

  Haughey, Bruce H ^a   Hinni, Michael L ^b   Salassa, John R ^c   Hayden, Richard E ^b   Grant, David G ^c   Rich, Jason T ^a   Milov, Simon ^a   Lewis Jr , James S ^a   Krishna, Murli ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

Author keywords

base of tongue cancer; human papillomavirus; laser; minimally invasive; tonsil cancer

Indexed keywords

PROTEIN P16;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CONTROLLED STUDY; DATA BASE; DISEASE FREE SURVIVAL; DYSPHAGIA; FEMALE; FOLLOW UP; HUMAN; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; NECK DISSECTION; OROPHARYNX CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SURGICAL TECHNIQUE; SURVIVAL TIME; SWALLOWING; TONGUE CANCER; TONSIL CANCER; TRANSORAL LASER MICROSURGERY; TREATMENT OUTCOME; WART VIRUS;

ADULT; AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LASER THERAPY; MALE; MICROSURGERY; MIDDLE AGED; NECK DISSECTION; NEOPLASMS, SQUAMOUS CELL; OROPHARYNGEAL NEOPLASMS; SURGICAL PROCEDURES, MINIMALLY INVASIVE; SURVIVAL RATE;

EID: 79958272187     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21669     Document Type: Article

References (45)

1. Shiboski CH, Schmidt BL, Jordan RC,. Tongue and tonsil carcinoma increasing trends in the U.S. population ages 20-44 years. Cancer 2005; 103: 1843-1849. (Pubitemid 40563256)
2. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709-720. (Pubitemid 30365531)
3. Forastiere AA, Trotti A,. Radiotherapy and concurrent chemotherapy: a strategy that improves locoregional control and survival in oropharyngeal cancer. J Natl Cancer Inst 1999; 91: 2065-2066. (Pubitemid 30019565)
4. Finnegan V, Parsons JT, Greene BD, Sharma V,. Neoadjuvant chemotherapy followed by concurrent hyperfractionated radiation therapy and sensitizing chemotherapy for locally advanced (T3-T4) oropharyngeal squamous cell carcinoma. Head Neck 2009; 31: 167-174.
5. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced stage oropharynx carcinoma. J Clin Oncol 2004; 22: 69-76. (Pubitemid 41095116)
6. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91: 2081-2086. (Pubitemid 30019568)
7. Zafereo ME, Hanasono MM, Rosenthal DI, et al. The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx. Cancer 2009: 15; 115: 5723-5733.
8. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
9. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098. (Pubitemid 37464533)
10. Garden AS, Harris J, Trotti A, et al. Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14). Int J Radiation Oncology Biol Phys 2008; 71: 1351-1355. (Pubitemid 351978166)
11. Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008; 26: 3582-3589.
12. Seikaly H, Rieger J, Wolfaardt J, Moysa G, Harris MD, Naresh J,. Functional outcomes after primary oropharyngeal cancer resection and reconstruction with the radial forearm free flap. Laryngoscope 2003; 113: 897-904. (Pubitemid 36539167)
13. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006; 24: 5630-5636. (Pubitemid 46631302)
14. Fischer CA, Zlobec I, Green E, et al. Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality? Int J Cancer 2010; 126: 1256-1262.
15. Steiner W, Fierek O, Ambrosch P, Hommerich CP, Kron M,. Transoral laser microsurgery for squamous cell carcinoma of the base of tongue. Arch Otolaryngol Head Neck Surg 2003; 129: 36-43. (Pubitemid 36070874)
16. Vaughn CW, Strong MS, Shapshay SM,. Modern technology in cancer therapy: status of carbon dioxide laser. Otolaryngol Clin North Am 1980; 13: 459-465. (Pubitemid 10027310)
17. Steiner W, Ambrosch P, Knappe MV,. Endoscopic laser surgery of the upper aerodigestive tract: with special emphasis on cancer surgery. New York: Thieme Medical Publishers; 2001.
18. Hinni ML, Salassa JR, Grant DG, et al. Transoral laser microsurgery for advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg 2007; 133: 1198-1204. (Pubitemid 350294247)
19. Grant DG, Salassa JR, Hinni ML, Pearson BW, Perry WC,. Carcinoma of the tongue base treated by transoral laser microsurgery, Part I: untreated tumors, a prospective analysis of oncologic and functional outcomes. Laryngoscope 2006: 116: 2150-2155. (Pubitemid 44912310)
20. Rich JT, Milov S, Lewis JS Jr, Thorstad WL, Adkins D, Haughey BH,. Transoral laser microsurgery (TLM) ± adjuvant therapy for advanced stage oropharyngeal cancer: outcomes and prognostic factors. Laryngoscope 2009; 119: 1709-1719.
21. Klussmann JP, Gultekin E, Weissenborn SJ, et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 2003; 162: 747-753. (Pubitemid 36237483)
22. El-Mofty SK, Patil S,. Human papillomavirus (HPV)-related oropharyngeal nonkeratinizing squamous cell carcinoma: characterization of a distinct phenotype. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101: 339-345. (Pubitemid 43303813)
23. Chernock RD, El-Mofty SK, Thorstad WL, Parvin CA, Lewis JS Jr,. HPV-related nonkeratinizing squamous cell carcinoma of the oropharynx: utility of microscopic features in predicting patient outcome. Head and Neck Pathol 2009; 3: 186-194.
24. Salassa JR,. A functional outcome swallowing scale for staging oropharyngeal dysphagia. Dig Dis 1999; 17: 230-234. (Pubitemid 30198257)
25. Centers for Disease Control and Prevention (CDC). Tobacco use: United States, 1900-1999. MMWR, Morb Mortal Wkly Rep 1999; 48: 986-993.
26. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96. (Pubitemid 351521864)
27. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-269. (Pubitemid 351480538)
28. Wolf GT, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer: the Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991; 324: 1685-1690.
29. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098. (Pubitemid 37464533)
30. Forastiere AA, Maor M, Weber RS,. Long-term results of Intergroup RTOG 91-11: a phase III trial to preserve the larynx: induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2006; 24 (Suppl 18): 5517.
31. Nguyen NP, Vos P, Smith HJ, et al. Concurrent chemoradiation for locally advanced oropharyngeal cancer. Am J Otolaryngol 2007; 28: 3-8. (Pubitemid 44879644)
32. Urba SG, Moon J, Giri S, et al. Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a southwest oncology group trial. J Clin Oncol 2005; 23: 88-95. (Pubitemid 41702626)
33. Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 2008; 26: 1-11.
34. Huang K, Xia P, Chuang C, et al. Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma the University of California-San Francisco experience. Cancer 2008; 113: 497-507.
35. Cmelak AJ, Li S, Goldwasser MA, et al. Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx; results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol 2007; 25: 3971-3977. (Pubitemid 47477276)
36. Duvvuri U, Myers JN, Contemporary management of oropharyngeal cancer: anatomy and physiology of the oropharynx. Curr Probl Surg 2009; 46: 119-184.
37. Cooper JS, Pajak TF, Forastiere A, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-1944.
38. Greven K, White D, Brown J, et al. Swallowing dysfunction is a common sequel after chemoradiation for oropharynx carcinoma. Am J Clin Oncol 2008; 31: 209-212.
39. Wolf GT,. Tradition, teamwork, and tailored treatment surgical oncology in the genomic era. Arch Otolaryngol Head Neck Surg 2009; 135: 337-341.
40. Lewis JS Jr, Thorstad WL, Chernock RD, et al. p16 positive oropharyngeal squamous cell carcinoma: an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol 2010; 34: 1088-1096.
41. Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007; 121: 2465-2472. (Pubitemid 350022416)
42. Walvekar RR, Li RJ, Gooding WE, et al. Role of surgery in limited (T1-2, N0-1) cancers of the oropharynx. Laryngoscope 2008; 118: 2129-2134.
43. Cooper JS, Pajak TF, Forastiere A, et al. Precisely defining high-risk operable head and neck tumors based on RTOG #85-03 and #88-24: targets for postoperative radiochemotherapy? Head Neck 1998; 20: 588-594. (Pubitemid 28405799)
44. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 2005; 27: 843-850. (Pubitemid 41395696)
45. Pradier O, Christiansen H, Schmidberger H, et al. Adjuvant radiotherapy after transoral laser microsurgery for advanced squamous carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2005; 63: 1368-1377. (Pubitemid 41628031)